Antisoma, a biotechnology company specializing in the development of novel drugs for the treatment of cancer, released a statement that the vaccine ASA404 improves anticancer responses and survival for patients with non-small cell lung cancer.

ASA404 is known as a vascular disrupting agent (VDA). ASA404 is different from angiogenenesis inhibitors that disrupt the new formation of blood vessels. This vaccine disrupts established blood vessels that feed cancer cells.

The researchers concluded that ASA404 appears promising in the treatment of advanced non-small cell lung cancer. A Phase III clinical trial is expected to begin in 2008. This is the last step prior to FDA review.

Tarceva (erlotinib) and Iressa (gefitnib) are both agents targeted against the EGFR pathway. This pathway is involved in cell growth and replication and when mutated or altered, excessive replication of cells can occur. These agents reduce the uncontrolled replication and growth of cancer cells by blocking mutated EGFR pathways.

According to an article published in the Journal of Clinical Oncology, the targeted agent Tarceva may provide anticancer responses for patients with non-small cell lung cancer (NSCLC) who stop responding to Iressa. These drugs are not associated with the side effects of chemotherapy, providing an effective alternative for patients who are not eligible for standard therapy.

A study was done to evaluate the effectiveness of Tarceva among patients who stopped responding to Iressa. The researchers concluded that -- Patients with NSCLC who demonstrate disease control with Iressa and do not have EGFR mutations appear to have benefit from treatment with Tarceva once their cancer progresses following their treatment with Iressa. Patients with recurrent NSCLC may wish to speak with their physician regarding their individual risks and benefits of treatment with Tarceva.